Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies
- PMID: 23831709
- DOI: 10.1038/nbt.2621
Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies
Abstract
By enabling the simultaneous engagement of two distinct _targets, bispecific antibodies broaden the potential utility of antibody-based therapies. However, bispecific-antibody design and production remain challenging, owing to the need to incorporate two distinct heavy and light chain pairs while maintaining natural nonimmunogenic antibody architecture. Here we present a bispecific-antibody production strategy that relies on co-culture of two bacterial strains, each expressing a half-antibody. Using this approach, we produce 28 unique bispecific antibodies. A bispecific antibody against the receptor tyrosine kinases MET and EGFR binds both _targets monovalently, inhibits their signaling, and suppresses MET and EGFR-driven cell and tumor growth. Our strategy allows rapid generation of bispecific antibodies from any two existing antibodies and yields milligram to gram quantities of bispecific antibodies sufficient for a wide range of discovery and preclinical applications.
Comment in
-
Bispecific antibodies with native chain structure.Nat Biotechnol. 2014 Feb;32(2):136-7. doi: 10.1038/nbt.2812. Nat Biotechnol. 2014. PMID: 24509759 No abstract available.
Similar articles
-
Bispecific antibodies with native chain structure.Nat Biotechnol. 2014 Feb;32(2):136-7. doi: 10.1038/nbt.2812. Nat Biotechnol. 2014. PMID: 24509759 No abstract available.
-
Impact of Cell-surface Antigen Expression on _target Engagement and Function of an Epidermal Growth Factor Receptor × c-MET Bispecific Antibody.J Biol Chem. 2015 Oct 9;290(41):24689-704. doi: 10.1074/jbc.M115.651653. Epub 2015 Aug 10. J Biol Chem. 2015. PMID: 26260789 Free PMC article.
-
A novel glycoengineered bispecific antibody format for _targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties.J Biol Chem. 2014 Jul 4;289(27):18693-706. doi: 10.1074/jbc.M113.528109. Epub 2014 May 19. J Biol Chem. 2014. PMID: 24841203 Free PMC article.
-
The use of CrossMAb technology for the generation of bi- and multispecific antibodies.MAbs. 2016 Aug-Sep;8(6):1010-20. doi: 10.1080/19420862.2016.1197457. Epub 2016 Jun 10. MAbs. 2016. PMID: 27285945 Free PMC article. Review.
-
Engineering therapeutic bispecific antibodies using CrossMab technology.Methods. 2019 Feb 1;154:21-31. doi: 10.1016/j.ymeth.2018.11.008. Epub 2018 Nov 16. Methods. 2019. PMID: 30453028 Review.
Cited by
-
Full-length recombinant antibodies from Escherichia coli: production, characterization, effector function (Fc) engineering, and clinical evaluation.MAbs. 2022 Jan-Dec;14(1):2111748. doi: 10.1080/19420862.2022.2111748. MAbs. 2022. PMID: 36018829 Free PMC article. Review.
-
Exploring the biomarkers and potential therapeutic drugs for sepsis via integrated bioinformatic analysis.BMC Infect Dis. 2024 Jan 2;24(1):32. doi: 10.1186/s12879-023-08883-9. BMC Infect Dis. 2024. PMID: 38166628 Free PMC article.
-
Revolutionizing cancer immunotherapy: unleashing the potential of bispecific antibodies for _targeted treatment.Front Immunol. 2023 Dec 1;14:1291836. doi: 10.3389/fimmu.2023.1291836. eCollection 2023. Front Immunol. 2023. PMID: 38106416 Free PMC article. Review.
-
_targeted Treatment of Relapsed or Refractory Follicular Lymphoma: Focus on the Therapeutic Potential of Mosunetuzumab.Cancer Manag Res. 2023 Mar 14;15:257-264. doi: 10.2147/CMAR.S381493. eCollection 2023. Cancer Manag Res. 2023. PMID: 36941881 Free PMC article. Review.
-
The mosaic puzzle of the therapeutic monoclonal antibodies and antibody fragments - A modular transition from full-length immunoglobulins to antibody mimetics.Leuk Res Rep. 2022 Jun 27;18:100335. doi: 10.1016/j.lrr.2022.100335. eCollection 2022. Leuk Res Rep. 2022. PMID: 35832747 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous